Principia Biopharma Inc (PRNB) Given Average Rating of “Strong Buy” by Brokerages
Principia Biopharma Inc (NASDAQ:PRNB) has received a consensus broker rating score of 1.00 (Strong Buy) from the five analysts that cover the stock, Zacks Investment Research reports. Five investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus price objective of $43.00 for the company and are forecasting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also given Principia Biopharma an industry rank of 46 out of 255 based on the ratings given to related companies.
A number of equities research analysts have recently commented on PRNB shares. Zacks Investment Research lowered Principia Biopharma from a “buy” rating to a “sell” rating in a research report on Wednesday, January 9th. Stifel Nicolaus started coverage on Principia Biopharma in a research report on Tuesday. They set a “buy” rating and a $45.00 price target on the stock. Finally, Leerink Swann set a $42.00 price target on Principia Biopharma and gave the stock a “buy” rating in a research report on Thursday, March 21st.
NASDAQ:PRNB traded up $0.66 during mid-day trading on Friday, hitting $29.67. The company had a trading volume of 2,858 shares, compared to its average volume of 96,808. Principia Biopharma has a fifty-two week low of $22.00 and a fifty-two week high of $38.34. The firm has a market capitalization of $692.32 million and a price-to-earnings ratio of 51.67.
Principia Biopharma (NASDAQ:PRNB) last released its earnings results on Tuesday, March 19th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.68. The company had revenue of $26.14 million during the quarter, compared to analyst estimates of $13.70 million. As a group, sell-side analysts expect that Principia Biopharma will post -2.51 EPS for the current year.
Principia Biopharma Company Profile
Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.
Featured Article: What is a blue-chip stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.